GT-repeat polymorphism in the heme oxygenase-1 gene promoter is associated with cardiovascular mortality risk in an arsenic-exposed population in northeastern Taiwan

Journal Article · Mon Nov 01 00:00:00 EDT 2010 · Toxicology and Applied Pharmacology

DOI:https://doi.org/10.1016/j.taap.2010.08.005· OSTI ID:21460229

Wu, Meei-Maan ^[1]; Chiou, Hung-Yi ^[1]; Chen, Chi-Ling ^[2]; Wang, Yuan-Hung ^[3]; Hsieh, Yi-Chen ^[1]; Lien, Li-Ming ^[4]; Lee, Te-Chang ^[5]; Chen, Chien-Jen ^[6]

---

1. School of Public Health, Taipei Medical University, Taipei, Taiwan (China)
2. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (China)
3. Center of Excellence for Cancer Research, Taipei Medical University, Taipei, Taiwan (China)
4. Department of Neurology, Shin Kong WHS Memorial Hospital, Taipei, Taiwan (China)
5. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (China)
6. Genomics Research Center, Academia Sinica, Taipei, Taiwan (China)

Inorganic arsenic has been associated with increased risk of atherosclerotic vascular disease and mortality in humans. A functional GT-repeat polymorphism in the heme oxygenase-1 (HO-1) gene promoter is inversely correlated with the development of coronary artery disease and restenosis after clinical angioplasty. The relationship of HO-1 genotype with arsenic-associated cardiovascular disease has not been studied. In this study, we evaluated the relationship between the HO-1 GT-repeat polymorphism and cardiovascular mortality in an arsenic-exposed population. A total of 504 study participants were followed up for a median of 10.7 years for occurrence of cardiovascular deaths (coronary heart disease, cerebrovascular disease, and peripheral arterial disease). Cardiovascular risk factors and DNA samples for determination of HO-1 GT repeats were obtained at recruitment. GT repeats variants were grouped into the S (< 27 repeats) or L allele ({>=} 27 repeats). Relative mortality risk was estimated using Cox regression analysis, adjusted for competing risk of cancer and other causes. For the L/L, L/S, and S/S genotype groups, the crude mortalities for cardiovascular disease were 8.42, 3.10, and 2.85 cases/1000 person-years, respectively. After adjusting for conventional cardiovascular risk factors and competing risk of cancer and other causes, carriers with class S allele (L/S or S/S genotypes) had a significantly reduced risk of cardiovascular mortality compared to non-carriers (L/L genotype) [OR, 0.38; 95% CI, 0.16-0.90]. In contrast, no significant association was observed between HO-1 genotype and cancer mortality or mortality from other causes. Shorter (GT)n repeats in the HO-1 gene promoter may confer protective effects against cardiovascular mortality related to arsenic exposure.

• OSTI ID: 21460229
• Journal Information: Toxicology and Applied Pharmacology, Vol. 248, Issue 3; Other Information: DOI: 10.1016/j.taap.2010.08.005; PII: S0041-008X(10)00278-4; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0041-008X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
ARSENIC
CARDIOVASCULAR DISEASES
GENES
GENOTYPE
HEALTH HAZARDS
HEME
MORTALITY
NEOPLASMS
OXYGENASES
PROMOTERS
REGRESSION ANALYSIS
VASCULAR DISEASES
CARBOXYLIC ACIDS
DISEASES
ELEMENTS
ENZYMES
HAZARDS
HETEROCYCLIC ACIDS
HETEROCYCLIC COMPOUNDS
MATHEMATICS
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
OXIDOREDUCTASES
PIGMENTS
PORPHYRINS
PROTEINS
SEMIMETALS
STATISTICS